Some patients still have AML cells in their marrow even after treatment. This is called refractory leukemia.
有些患者甚至在治疗后其骨髓中仍然存有aml细胞。这叫做难治性白血病。
With refractory leukemia, drugs that were not used to treat the patient's AML in the first part of treatment may be given. Stem cell transplantation also may be used.
对于难治性白血病，可能会用到在AML第一阶段治疗中用不到的药，也可能会进行干细胞移植。
Clofarabine injection is indicated for the treatment of pediatric patients (ages 1-21 years) with relapsed or refractory acute lymphoblastic leukemia after at least 2 previous regimens.
氯法拉滨注射液适用于对至少2种治疗方案无效的儿童(1 - 21岁)难治性或复发性急性淋巴细胞白血病的治疗。
Objective to evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).
目的研究改良FLAG方案治疗难治性急性髓细胞白血病(aml)的疗效。
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
替匹法尼用一周，停一周剂量递增治疗复发性，难治性或高危髓细胞性白血病1阶段试验。
Bad reaction to treatment, low induced relieving rate, high recurrence rate, and short survival period are tough problem in the treatment of refractory acute leukemia (RAL).
难治性急性白血病对治疗反应差，诱导缓解率低，复发率高，生存期短，是白血病治疗中的难题，目前仍以联合化疗为主要治疗方法。
Bad reaction to treatment, low induced relieving rate, high recurrence rate, and short survival period are tough problem in the treatment of refractory acute leukemia (RAL).
难治性急性白血病对治疗反应差，诱导缓解率低，复发率高，生存期短，是白血病治疗中的难题，目前仍以联合化疗为主要治疗方法。
应用推荐